Meeting
2020 ASCO Virtual Scientific Program
Phase I/II open label nonrandomized safety and efficacy study of the viral vectored ChAdOx1-MVA 5T4 immunotherapy in combination with PD-1 checkpoint blockade in intermediate-risk localized or locally advanced prostate cancer and advanced metastatic prostate cancer.
Presenter
Mark Tuthill
The Jenner Institute, University of Oxford
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Vaccines
Clinical Trial Registration Number
NCT03815942
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS3170)
DOI
10.1200/JCO.2020.38.15_suppl.TPS3170
Abstract #
TPS3170
Poster Bd #
234
Abstract Disclosures
Similar Videos & Slides
Speaker: To Be Determined
Videos & Slides
2024 ASCO Annual Meeting
The efficacy and safety of RC88 in patients with ovarian cancer, non-squamous-non-small-cell lung-carcinoma and cervical cancer: Results from a first-in-human phase 1/2 study.
Speaker: Yutao Liu
Videos & Slides
2024 ASCO Annual Meeting
Preliminary results of phase I/II study to evaluate safety and efficacy of combination pucotenlimab with epidermal growth factor receptor-ADC (EGFR-ADC) MRG003 in patients with EGFR positive solid tumors.
Speaker: Dan-yun Ruan, MD
Videos & Slides
2024 ASCO Annual Meeting
Efficacy and safety of LM-108, an anti-CCR8 monoclonal antibody, in combination with an anti-PD-1 antibody in patients with gastric cancer: Results from phase 1/2 studies.
Speaker: Lin Shen, MD